In this review:
Pertuzumab is the first in a new class of targeted cancer treatments termed HER2 dimerization inhibitors.In New Zealand, pertuzumab is indicated in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with inflammatory or locally advanced HER2-positive breast cancer as part of a complete treatment regimen AND in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for their metastatic disease.
Download PDF